Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SAGE-319 by Sage Therapeutics for Unspecified Central Nervous System Disorders: Likelihood of Approval
SAGE-319 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders. According...
SAGE-689 by Sage Therapeutics for Unspecified Central Nervous System Disorders: Likelihood of Approval
SAGE-689 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders. According...
Brexanolone by Sage Therapeutics for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval
Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Post-Traumatic Stress Disorder (PTSD). According to...
Brexanolone by Sage Therapeutics for Alcohol Dependence: Likelihood of Approval
Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Alcohol Dependence. According to GlobalData, Phase...